Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology Group.

Katherine E Warren,Gilbert Vezina,Mark Krailo,Linda Springer,Allen Buxton,Cody J Peer,William D Figg, Chris William-Hughes,Sandy Kessel,Maryam Fouladi,Amar Gajjar,Daniel Bowers

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

引用 1|浏览12

暂无评分

摘要

Lenalidomide demonstrates a sufficient level of activity in children with low-grade glioma to warrant further exploration. Low-dose (20 mg/m/dose administered once daily × 21 days of each 28-day cycle) lenalidomide appears to have better tolerability with comparable activity.

查看译文

关键词

pilocytic astrocytomas,optic pathway gliomas,lenalidomide

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要